Phospho-Chk1 (Ser345) Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5121290-Each-of-1 | In Stock | ₹ 44,811.50 |
PIPA5121290 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 44,811.50
GST (18%): ₹ 8,066.07
Total Price: ₹ 52,877.57
Antigen
Phospho-Chk1 (Ser345)
Classification
Polyclonal
Conjugate
Unconjugated
Gene
Chek1
Gene Alias
C85740; Cell cycle checkpoint kinase; checkpoint kinase 1; checkpoint kinase 1 homolog; checkpoint kinase-1; Checkpoint, S. pombe, homolog of, 1; CHEK1; CHK1; CHK1 checkpoint homolog; Chk1-S; homolog of Chk1-S; HRD1 Protein; rad27; rad27 homolog; serine/threonine protein kinase CHK1; serine/threonine-protein kinase Chk1; Synoviolin; YBR1742; YBR274W
Host Species
Rabbit
Purification Method
Affinity Chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1111, 12649, 140583
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
Western Blot
Concentration
1.27 mg/mL
Formulation
PBS with 50% glycerol and 0.01% thimerosal; pH 7.3
Gene Accession No.
O14757, O35280, Q91ZN7
Gene Symbols
Chek1
Immunogen
A synthetic phosphorylated peptide around S345 of human Chk1 (NP_001265.2).
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Positive test controls include: HT-29, HepG2, C6
- The target is usually found in the following locations: Cytoplasm, Nucleus, centrosome, cytoskeleton, microtubule organizing center
- Immunogen sequence: SFSQP CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised
- CHK1 is a key mediator in the DNA damage-induced checkpoint network
- CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress
- When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase
- Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.